Does GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS Cause Malignant neoplasm progression? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Malignant neoplasm progression have been filed in association with GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS. This represents 5.8% of all adverse event reports for GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS.
5
Reports of Malignant neoplasm progression with GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS
5.8%
of all GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS reports
0
Deaths
0
Hospitalizations
How Dangerous Is Malignant neoplasm progression From GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS?
Of the 5 reports.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does GENETICALLY-MODIFIED AUTOLOGOUS T CELLS NOS Cause?
Disease progression (28)
Lymphoma (17)
Cytokine release syndrome (16)
Off label use (14)
Neutropenia (9)
Plasma cell myeloma refractory (9)
Pyrexia (8)
Atrial fibrillation (5)
Covid-19 (5)
Death (5)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)